17

Anti-TNF-alpha treatments are increasingly widely prescribed. Multiple side effects have been reported in recent years, in particular peripheral neuropathy. We report a case of sensory neuropathy occurring six months after the start of treatment with infliximab. This was in a 43-year-old female patient, followed for APS since 2016, who required treatment with infliximab. Six months later, the patient presented a picture of sensory neuropathy. The etiological workup remained negative, and the discontinuation of infliximab was accompanied by an improvement in symptomatology. The delay between the initiation of infliximab-based treatment and the onset of clinical manifestations, as well as the improvement after dose reduction, argue for the responsibility of infliximab in the occurrence of the sensory neuropathy.